Profile data is unavailable for this security.
About the company
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
- Revenue in USD (TTM)0.00
- Net income in USD-58.01m
- Incorporated2015
- Employees43.00
- LocationNextCure Inc9000 Virginia Manor Rd Ste 200BELTSVILLE 20705-4214United StatesUSA
- Phone+1 (240) 399-4900
- Fax+1 (302) 655-5049
- Websitehttps://www.nextcure.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lantern Pharma Inc | 0.00 | -18.92m | 29.97m | 24.00 | -- | 3.09 | -- | -- | -1.75 | -1.75 | 0.00 | 0.8684 | 0.00 | -- | -- | 0.00 | -86.16 | -32.94 | -104.31 | -34.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.20 | -- | 17.11 | -- |
| Harvard Apparatus Regenertv Tchnlgy Inc | 743.00k | -6.53m | 30.39m | 8.00 | -- | 19.56 | -- | 40.90 | -0.4029 | -0.4029 | 0.0459 | 0.0905 | 0.1891 | 9.21 | 371.50 | 92,875.00 | -166.09 | -292.39 | -227.59 | -1,068.06 | 16.29 | -- | -878.20 | -6,677.86 | 1.83 | -- | 0.00 | -- | 317.48 | -- | 14.30 | -- | -- | -- |
| Rein Therapeutics Inc | 0.00 | -58.89m | 31.28m | 11.00 | -- | 25.25 | -- | -- | -2.63 | -2.63 | 0.00 | 1.84 | 0.00 | -- | -- | 0.00 | -74.57 | -64.62 | -80.38 | -71.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.71 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -23.81m | 32.39m | 43.00 | -- | 2.90 | -- | -- | -5.24 | -5.24 | 0.00 | 1.32 | 0.00 | -- | -- | -- | -97.99 | -72.20 | -125.06 | -80.91 | -- | -- | -- | -- | 1.35 | -41.06 | 0.3996 | -- | -- | -- | 7.86 | -- | -57.33 | -- |
| Bioqual Inc | 46.54m | 453.25k | 33.55m | 108.00 | 74.02 | 0.938 | 12.22 | 0.7209 | 0.5068 | 0.5068 | 52.03 | 39.99 | 0.7111 | -- | 3.19 | -- | 0.6926 | 4.12 | 0.7745 | 4.83 | 12.85 | 16.15 | 0.974 | 4.03 | -- | -- | 0.00 | 32.81 | -16.60 | 1.06 | -316.79 | -- | -36.99 | -6.51 |
| NextCure Inc | 0.00 | -58.01m | 33.55m | 43.00 | -- | 1.42 | -- | -- | -24.19 | -24.19 | 0.00 | 8.84 | 0.00 | -- | -- | 0.00 | -89.28 | -27.70 | -105.20 | -28.91 | -- | -- | -- | -1,336.59 | -- | -- | 0.00 | -- | -- | -- | 11.27 | -- | -32.45 | -- |
| Cell Source Inc | 0.00 | -6.57m | 34.03m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Outlook Therapeutics Inc | 297.49k | -102.86m | 35.05m | 17.00 | -- | -- | -- | 117.83 | -2.71 | -2.71 | 0.0068 | -0.5971 | 0.0169 | 0.4221 | -- | 17,499.41 | -583.70 | -240.08 | -- | -- | -57.80 | -- | -34,576.16 | -22,354.50 | 0.2795 | -151.67 | -- | -- | -- | -- | 17.17 | -- | -- | -- |
| INmune Bio Inc | 50.00k | -49.89m | 35.36m | 22.00 | -- | 1.39 | -- | 707.17 | -2.14 | -2.14 | 0.0021 | 0.9546 | 0.0012 | -- | 0.0258 | 2,272.73 | -115.83 | -45.54 | -153.59 | -52.16 | -- | -- | -99,774.00 | -19,298.45 | -- | -942.22 | 0.00 | -- | -90.97 | -- | -40.24 | -- | -- | -- |
| Atara Biotherapeutics Inc | 151.93m | 23.40m | 35.40m | 38.00 | 2.24 | -- | 1.33 | 0.233 | 2.19 | 2.19 | 12.81 | -5.08 | 1.76 | 3.99 | 93.55 | 993,006.60 | 27.07 | -67.79 | -- | -93.07 | 81.63 | -- | 15.40 | -558.47 | 1.02 | 15.24 | 8.31 | -- | 1,404.02 | -- | 69.07 | -- | -46.73 | -- |
| Actinium Pharmaceuticals Inc | 90.00k | -34.60m | 35.56m | 37.00 | -- | 2.58 | -- | 395.15 | -1.11 | -1.11 | 0.0029 | 0.4419 | 0.0013 | -- | -- | 2,432.43 | -50.05 | -43.20 | -55.95 | -47.84 | -- | -- | -38,443.33 | -7,408.74 | -- | -- | 0.0009 | -- | -100.00 | -- | 21.66 | -- | -29.66 | -- |
| CervoMed Inc | 6.16m | -25.58m | 35.99m | 15.00 | -- | 1.38 | -- | 5.84 | -2.87 | -2.87 | 0.6919 | 2.81 | 0.155 | -- | 7.58 | 410,652.00 | -64.37 | -54.89 | -71.42 | -60.99 | -- | -- | -415.36 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -34.88m | 36.24m | 24.00 | -- | 3.49 | -- | -- | -0.8194 | -0.8194 | 0.00 | 0.1982 | 0.00 | -- | -- | 0.00 | -80.05 | -57.93 | -125.74 | -68.38 | -- | -- | -- | -- | -- | -8.43 | 0.6552 | -- | -- | -- | 12.42 | -- | -- | -- |
| Xilio Therapeutics Inc | 31.80m | -58.49m | 36.53m | 64.00 | -- | -- | -- | 1.15 | -0.6571 | -0.6571 | 0.3348 | -0.1562 | 0.3053 | -- | -- | 496,937.50 | -56.14 | -67.88 | -102.68 | -81.71 | -- | -- | -183.90 | -5,578.28 | -- | -2.84 | -- | -- | -- | -- | 23.77 | -- | -45.00 | -- |
| Cypherpunk Technologies Inc | 0.00 | -50.81m | 36.86m | 52.00 | -- | 10.01 | -- | -- | -1.23 | -1.23 | 0.00 | 0.065 | 0.00 | -- | -- | 0.00 | -132.94 | -79.03 | -196.76 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to NextCure Inc's reporting currency: US Dollar USD
52.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Affinity Asset Advisors LLCas of 31 Dec 2025 | 247.29k | 9.24% |
| Ikarian Capital LLCas of 31 Dec 2025 | 238.30k | 8.91% |
| Squadron Capital Management LLCas of 31 Dec 2025 | 236.97k | 8.86% |
| SilverArc Capital Management LLCas of 31 Dec 2025 | 176.06k | 6.58% |
| Exome Asset Management LLCas of 31 Dec 2025 | 165.00k | 6.17% |
| AWM Investment Co., Inc.as of 31 Dec 2025 | 117.37k | 4.39% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 82.28k | 3.07% |
| Boothbay Fund Management LLCas of 31 Dec 2025 | 69.62k | 2.60% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 33.63k | 1.26% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 26.77k | 1.00% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
